Evidence map›Paper›PMID 40779221›Full record

ReviewJournal of natural medicines2025

Investigation and development of natural products that target chemotherapy resistance factors in cancer cells.

Takahiro Matsumoto

Abstract readReview
In one paragraph

Review in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Takahiro MatsumotoDivision of Biological Sciences-Laboratory of Public Health, Kyoto Pharmaceutical University, Yamashina-Ku, Misasagi, Kyoto, 607-8412, Japan. tmatsumo@mb.kyoto-phu.ac.jp.ORCID http://orcid.org/0000-0003-2408-669X

Funding

JSPS KAKENHI 20H03397JSPS KAKENHI 25K10025
6 · The paper itself

Abstract

Heat shock proteins (HSPs) play an important role in several tumors; contribute to anti-cancer drug resistance, cell proliferation, and metastasis; and have been suggested as a major cause of failed anti-cancer drug treatment. In addition, cancer stem cells (CSCs) have been identified in many types of malignancies, including leukemia, breast, colorectal, and brain cancers, and are a leading cause of failed cancer treatment owing to their anti-cancer drug and radiation therapy resistance. Therefore, many researchers, including our group, have investigated and developed natural products that target chemotherapy resistance factors in cancer cells. This review introduces the inhibitors of chemotherapy resistance factors discovered using a unique assay system.

Indexed as

Antineoplastic AgentsBiological ProductsDrug Resistance, NeoplasmNeoplasmsAnimalsHeat-Shock ProteinsHumansNeoplastic Stem CellsAntineoplastic AgentsBiological ProductsHeat-Shock ProteinsCancer stem cellChemotherapy resistance factorHeat shock proteinWnt/β-catenin pathway

Identifiers

PMID40779221
PMCPMC12408793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.